glp-1 forms Companies seek a second obesity treatment revolution—in pill form | Science Comparing Ozempic, Wegovy and Other
Description
doi: 10.3390/biomedicines10040778
Finally, heterogeneity may be attributed to study design and methodology differences, e.g., randomization, blinding and data collection
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes
Intern Med J (2020) 50(1):249
Gmez-Vaquero, C
Diabetes Care 30 , 15441548 (2007)
